Researchers have found that capsaicin cream is an effective and safe method of treating cannabinoid hyperemesis syndrome (CHS) in adolescents. Capsaicin cream has previously been shown to be effective at treating CHS in adults but adolescents have previously been treated with haloperidol, a drug known to have serious side effects. Capsaicin cream offers a much safer and more cost-effective method of treatment for adolescents.
Association of Marijuana Use and Cyclic Vomiting Syndrome
A recent study has found that a subset of patients diagnosed with Cyclic Vomiting Syndrome actually suffers from Cannabinoid Hyperemesis Syndrome. Cannabinoid Hyperemesis Syndrome is a rare condition that primarily occurs in daily, long-term users of cannabis, more common among males than females. Chronic cannabis consumers should inform their physicians of any illicit drug use, as well as any cannabis consumption, during routine check-ups and/or emergency room visits, to ensure accurate diagnoses can be made.
Training and Practices of Cannabis Dispensary Staff
How much medical training does your local budtender possess? An online survey sent to medical marijuana dispensary staff reported only 55% of staffers had any formal training for their position, with 20% reporting some background in medical/scientific training. The analysis reported that many among the dispensary staff are recommending cannabis choices that are consistent with current evidence, but some are recommending strains that are either ineffective or exacerbate a patient’s condition. The findings of this study stress the importance of consistent and well-regulated training of dispensary staff.
Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers
A study performed on daily cannabis users with cannabis use disorder (CUD) found evidence for Guanfacine to reduce the irritability and disturbances to sleep, characteristic of cannabis withdrawal. It is potentially a viable, improved alternative to Lofexidine, another treatment for CUD which happens to result in some adverse effects, including drowsiness, dizziness, and altered food intake. However, beyond these effects, while Lofexidine reduced cannabis self-administration following abstinence, Guanfacine did not in this study. Regardless, further research on the therapeutic effects of Guanfacine may be worthwhile and could help reduce cannabis cravings following withdrawal.
DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults
Cannabis withdrawal syndrome affects approximately 12.1% of heavy cannabis users and is characterized by symptoms such as nervousness/anxiety, hostility, sleep difficulty, and depressed mood. It has increased prevalence among those suffering from mood disorders, anxiety disorders, and personality disorders. This new data should emphasize the need for physicians to exercise caution when recommending cannabis to individuals who may end up consuming cannabis heavily, and who also suffering from mood, anxiety, or personality disorders